beta cell

**Location & Histology** - Found in the islets of Langerhans (endocrine pancreas, ~1-2% of pancreatic mass), mainly in the islet core. Other islet cells: alpha (glucagon, periphery, ~20%), delta (somatostatin, ~5-10%), PP cells (pancreatic polypeptide), epsilon (ghrelin). - Derived from the endoderm (pancreatic bud). Key transcription factors: PDX-1 (also called IPF1), NKX6.1, MafA. MODY is caused by mutations in several of these (HNF1A, HNF4A, HNF1B, glucokinase).

**Insulin synthesis** - Preproinsulin is made in the rough ER and cleaved to proinsulin. Proinsulin is packaged in the Golgi into secretory granules, where prohormone convertases cleave it into **insulin (A and B chains linked by disulfide bonds) and C-peptide in equimolar amounts**. Amylin (IAPP) is co-secreted. - C-peptide is a marker of endogenous insulin production. It is **low in type 1 DM** and **high in insulinoma or sulfonylurea abuse**. It is **low/absent in exogenous insulin administration (factitious hypoglycemia)**.

**Glucose-stimulated insulin secretion (high-yield mechanism)** 1. Glucose enters the beta cell through **GLUT2** (insulin-independent). 2. **Glucokinase** (the "glucose sensor," low affinity/high Km) phosphorylates glucose to glucose-6-phosphate. 3. Glycolysis and oxidative phosphorylation raise the **ATP/ADP ratio**. 4. ATP closes the **ATP-sensitive K⁺ channel (K-ATP; Kir6.2 + SUR1 subunits)**, which depolarizes the membrane. 5. Depolarization opens **voltage-gated L-type Ca²⁺ channels**. Ca²⁺ influx triggers exocytosis of insulin granules. - **Biphasic release:** a rapid first phase (release of stored, docked granules), then a slower sustained second phase (newly synthesized insulin).

**Modulators of secretion** - Stimulate: glucose, amino acids (arginine, leucine), GLP-1 and GIP (incretins, acting through cAMP, so an oral glucose load gives a larger insulin response than IV glucose), vagal (M3) stimulation, β2-adrenergic stimulation, glucagon, and sulfonylureas. - Inhibit: **α2-adrenergic stimulation (sympathetic)**, somatostatin, and diazoxide (opens K-ATP channels).

**Pharmacology** - **Sulfonylureas (glipizide, glyburide, glimepiride) and meglitinides (repaglinide, nateglinide):** close the K-ATP channel (SUR1) → insulin release. They can cause hypoglycemia and weight gain. Sulfonylureas require functioning beta cells. - **GLP-1 agonists (exenatide, liraglutide, semaglutide) and DPP-4 inhibitors (-gliptins):** increase glucose-dependent insulin secretion. - **Thiazolidinediones** (PPAR-γ) improve insulin sensitivity but do not stimulate beta cells directly. - **Diazoxide:** opens K-ATP channels, so it is used to treat hyperinsulinism or insulinoma. - **Neonatal diabetes:** gain-of-function mutations in Kir6.2 (KCNJ11) or SUR1 (ABCC8) keep K-ATP channels open, so insulin is not released. This is treated with sulfonylureas. Loss-of-function mutations cause congenital hyperinsulinism.

**Pathology** - **Type 1 DM:** autoimmune T-cell–mediated destruction of beta cells (HLA-DR3/DR4; autoantibodies to GAD65, IA-2, insulin, and ZnT8). Insulitis (lymphocytic infiltrate) is seen. It leads to absolute insulin deficiency, risk of DKA, and low C-peptide. - **Type 2 DM:** peripheral insulin resistance and progressive beta cell dysfunction/loss. Islets show **amyloid deposition (amylin/IAPP)**, and beta cell mass decreases over time (glucotoxicity/lipotoxicity). - **Insulinoma:** beta cell tumor. Whipple triad: symptoms of hypoglycemia, low plasma glucose, and relief with glucose. Labs show high insulin, high C-peptide, and high proinsulin. It is associated with MEN1 (the 3 Ps: pituitary, parathyroid, pancreas). - **Neonatal/transient hyperinsulinism:** seen in infants of diabetic mothers (fetal beta cell hyperplasia → macrosomia, neonatal hypoglycemia). - Beta cells are susceptible to destruction by **alloxan** and **streptozotocin** (toxic glucose analogs; used in experimental diabetes models, and streptozotocin is also used to treat islet cell tumors).

**Actions of insulin (target tissues)** - ↑ glucose uptake through **GLUT4** in skeletal muscle and adipose tissue (not the liver, brain, RBCs, or beta cells, which use other transporters). - ↑ glycogen, fat, and protein synthesis; ↓ gluconeogenesis, glycogenolysis, lipolysis, and ketogenesis. - ↑ cellular K⁺ uptake through Na⁺/K⁺-ATPase. This is why insulin is used to treat hyperkalemia.

**Clinical pearl:** In the hospitalized patient with unexplained hypoglycemia, measure insulin, C-peptide, proinsulin, and a sulfonylurea screen. High insulin with *low* C-peptide points to exogenous insulin. High insulin with *high* C-peptide points to an insulinoma or a sulfonylurea.